Tata Elxsi shares jump nearly 1% ahead of Q1 FY26 results announcement
Tata Elxsi shares gained nearly 1% in early trade on Thursday, climbing to a high of ₹6,174 on the NSE, as investors await the company's Q1 FY26 earnings. The stock opened at ₹6,130 and touched an intraday low of ₹6,052.50. As of 12:34 PM, the shares were trading 0.19% higher at Rs 6,163.50.
Investor sentiment remains cautiously optimistic ahead of the results, as the market looks for cues on the company's performance in the embedded systems and design-led digital engineering space.
At current levels, Tata Elxsi is still trading well below its 52-week high of ₹9,080, but significantly above the 52-week low of ₹4,700, reflecting ongoing volatility and selective buying interest.
The Q1 numbers will be closely watched for revenue growth, margin trends, and deal momentum in key verticals like automotive, media, and healthcare.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Travel Weekly
12 hours ago
- Travel Weekly
Aman resort coming to Saudi Arabia
Aman has unveiled plans for Amansamar, a luxury resort and residential complex within Saudi Arabia's Wadi Safar mega-development. Located near Riyadh's UNESCO's World Heritage Site of Diriyah, Wadi Safar will be home to a golf course, equestrian and polo facilities, and additional hotels, including Six Senses, Oberoi, Montage and Faena hotels, among others. Amansamar will have 80 guestrooms and 37 branded residences with five and six bedrooms. Guests and residents will have access to the Aman Spa with hammam and banya facilities, multiple dining venues, a racquet club, pools, and a kids' club. Amansamar is under construction. It will join Aman's growing footprint in the Middle East, which includes the Janu Diriyah and Aman AlUla in Saudi Arabia as well as the Aman Dubai and Janu Dubai.
Business Upturn
17 hours ago
- Business Upturn
Wockhardt exits US generics business to focus on innovative portfolio
Wockhardt has announced a major strategic shift in its US operations, marking a significant step in its journey to become a future-ready, innovation-driven pharmaceutical company. As part of this realignment, the company has decided to exit the US generic pharmaceutical market and focus instead on high-value, research-based areas such as new antibiotic drug discovery and biological insulin products. The move follows years of financial strain in the US generics segment, which recorded a loss of nearly $8 million in FY 2025 alone. After a detailed strategic review, Wockhardt has opted for a clean and structured exit by filing for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its wholly owned subsidiaries—Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. This bold decision, effective July 11, 2025, will allow Wockhardt to reallocate resources and management bandwidth to its advanced product pipeline, particularly in antibiotics and insulin-based therapies. The company has already established a strong global position in new antibiotic discovery and is leveraging cutting-edge technology in its biologicals portfolio to address unmet needs in diabetes care. Wockhardt remains firmly committed to its operations in India, the UK, Ireland, and other global markets where its businesses continue to perform strongly. This strategic evolution reflects Wockhardt's commitment to innovation, scientific excellence, and long-term value creation for patients, partners, and shareholders. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
17 hours ago
- Business Upturn
Gland Pharma gets GMP certification for Pashamylaram facility from Danish Medicines Agency
By Aman Shukla Published on July 11, 2025, 16:07 IST Gland Pharma has announced that its Pashamylaram facility has received a Good Manufacturing Practices (GMP) Compliance Certificate from the Danish Medicines Agency. This certification is crucial for marketing authorizations involving manufacturers outside the European Economic Area (EEA). The approval specifically covers the company's aseptically prepared powder products used for injection, infusion, and inhalation. The recognition underscores Gland Pharma's commitment to maintaining global manufacturing standards and strengthens its position in international markets. In the exchange filings, the company shared, 'This is to inform you that the Pashamylaram Facility of the Company has received certificate of Good Manufacturing Practices (GMP) Compliance from Danish Medicines Agency in connection with Marketing authorizations listing manufacturers located outside of the European Economic Area, for aseptically prepared Powder for injection, infusion and inhalation.' This GMP certification will enable Gland Pharma to continue expanding its reach in Europe and support the export of critical injectable and inhalable formulations. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
